Zacks Research Forecasts Haemonetics’ Q3 Earnings (NYSE:HAE)

Haemonetics Corporation (NYSE:HAE) – Equities researchers at Zacks Research boosted their Q3 2027 earnings per share estimates for Haemonetics in a research report issued to clients and investors on Tuesday, March 24th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn $1.42 per share for the quarter, up from their prior estimate of $1.41. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2027 earnings at $1.35 EPS.

A number of other equities research analysts also recently issued reports on the stock. CJS Securities upgraded shares of Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th. BTIG Research restated a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a report on Friday, February 6th. Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Robert W. Baird set a $81.00 price target on shares of Haemonetics in a report on Friday, February 6th. Finally, Mizuho dropped their price target on Haemonetics from $90.00 to $80.00 and set an “outperform” rating for the company in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and a consensus target price of $83.89.

Haemonetics Trading Down 2.8%

HAE stock opened at $53.96 on Thursday. The firm has a fifty day moving average price of $62.27 and a 200 day moving average price of $64.89. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $87.32. The firm has a market cap of $2.51 billion, a PE ratio of 14.86, a price-to-earnings-growth ratio of 1.16 and a beta of 0.28. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.15 and a current ratio of 1.75.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. The business had revenue of $338.97 million for the quarter, compared to the consensus estimate of $331.90 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The company’s revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS.

Institutional Trading of Haemonetics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. lifted its holdings in shares of Haemonetics by 1,405.7% in the 3rd quarter. Federated Hermes Inc. now owns 46,104 shares of the medical instruments supplier’s stock worth $2,247,000 after buying an additional 43,042 shares during the period. Boston Partners increased its stake in shares of Haemonetics by 2.2% during the second quarter. Boston Partners now owns 543,169 shares of the medical instruments supplier’s stock valued at $40,660,000 after buying an additional 11,738 shares during the period. Harbor Capital Advisors Inc. increased its stake in shares of Haemonetics by 49.7% during the third quarter. Harbor Capital Advisors Inc. now owns 42,859 shares of the medical instruments supplier’s stock valued at $2,089,000 after buying an additional 14,226 shares during the period. Isthmus Partners LLC raised its holdings in shares of Haemonetics by 36.5% in the third quarter. Isthmus Partners LLC now owns 61,702 shares of the medical instruments supplier’s stock valued at $3,007,000 after acquiring an additional 16,505 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH raised its holdings in shares of Haemonetics by 36.2% in the third quarter. Fort Washington Investment Advisors Inc. OH now owns 706,312 shares of the medical instruments supplier’s stock valued at $34,426,000 after acquiring an additional 187,630 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.